Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 183 participants.

Also called NCT06872684

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 183 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06872684
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06872684. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2029-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Acronym
GUARD
Condition
Aneurysm
Condition
Aneurysm, Intracranial
Intervention (Device)
Surpass Elite with Guardian Flow Diverter System
Lead sponsor
Stryker Neurovascular (class: industry)

Record details

Record id
cardio:ct-nct06872684
Content hash
200bb99bd957b495118d89caa6724e215f6989773f27f47e8de2fdbff670992f